223 related articles for article (PubMed ID: 25565774)
1. Clinicopathological significance and potential drug target of T-cadherin in NSCLC.
Wang Z; Wang B; Guo H; Shi G; Hong X
Drug Des Devel Ther; 2015; 9():207-16. PubMed ID: 25565774
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological significance and potential drug target of RUNX3 in non-small cell lung cancer: a meta-analysis.
Xu L; Lan H; Su Y; Li J; Wan J
Drug Des Devel Ther; 2015; 9():2855-65. PubMed ID: 26082616
[TBL] [Abstract][Full Text] [Related]
3. The clinicopathological significance and potential drug target of E-cadherin in NSCLC.
Zhong K; Chen W; Xiao N; Zhao J
Tumour Biol; 2015 Aug; 36(8):6139-48. PubMed ID: 25758052
[TBL] [Abstract][Full Text] [Related]
4. A meta-analysis for CXCR4 as a prognostic marker and potential drug target in non-small cell lung cancer.
Zhang C; Li J; Han Y; Jiang J
Drug Des Devel Ther; 2015; 9():3267-78. PubMed ID: 26150700
[TBL] [Abstract][Full Text] [Related]
5. The clinicopathological significance of FHIT hypermethylation in non-small cell lung cancer, a meta-analysis and literature review.
Yan W; Xu N; Han X; Zhou XM; He B
Sci Rep; 2016 Jan; 6():19303. PubMed ID: 26796853
[TBL] [Abstract][Full Text] [Related]
6. The clinicopathological significance and ethnic difference of FHIT hypermethylation in non-small-cell lung carcinoma: a meta-analysis and literature review.
Wu X; Wu G; Yao X; Hou G; Jiang F
Drug Des Devel Ther; 2016; 10():699-709. PubMed ID: 26929601
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological significance of CXCR4 in non-small cell lung cancer.
Zhou XM; He L; Hou G; Jiang B; Wang YH; Zhao L
Drug Des Devel Ther; 2015; 9():1349-58. PubMed ID: 25834393
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of CDH13 hypermethylation and mRNA in NSCLC.
Xue R; Yang C; Zhao F; Li D
Onco Targets Ther; 2014; 7():1987-96. PubMed ID: 25382980
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological significance and a potential drugtarget of RARβ in non-small-cell lung carcinoma: a meta-analysis and a systematic review.
Song X; Shi K; Zhou SJ; Yu DP; Liu Z; Han Y
Drug Des Devel Ther; 2016; 10():1345-54. PubMed ID: 27103788
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological significance and potential drug targeting of CDH1 in lung cancer: a meta-analysis and literature review.
Yu Q; Guo Q; Chen L; Liu S
Drug Des Devel Ther; 2015; 9():2171-8. PubMed ID: 25931811
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of angiopoietin-2 in non-small cell lung cancer patients: a meta-analysis.
Xuan ZX; Zhang S; Yuan SJ; Wang W; Yu J
World J Surg Oncol; 2016 Sep; 14(1):237. PubMed ID: 27589869
[TBL] [Abstract][Full Text] [Related]
12. Association between Retinoic acid receptor-β hypermethylation and NSCLC risk: a meta-analysis and literature review.
Li Y; Lu DG; Ma YM; Liu H
Oncotarget; 2017 Jan; 8(4):5814-5822. PubMed ID: 28008143
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological significance of WIF1 hypermethylation in NSCLC, a meta-analysis and literature review.
Guo H; Zhou S; Tan L; Wu X; Wu Z; Ran R
Oncotarget; 2017 Jan; 8(2):2550-2557. PubMed ID: 27911280
[TBL] [Abstract][Full Text] [Related]
14. The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials.
Hasegawa Y; Ando M; Maemondo M; Yamamoto S; Isa S; Saka H; Kubo A; Kawaguchi T; Takada M; Rosell R; Kurata T; Ou SH
Oncologist; 2015 Mar; 20(3):307-15. PubMed ID: 25657199
[TBL] [Abstract][Full Text] [Related]
15. Aberrant methylation of H-cadherin (CDH13) promoter is associated with tumor progression in primary nonsmall cell lung carcinoma.
Kim JS; Han J; Shim YM; Park J; Kim DH
Cancer; 2005 Nov; 104(9):1825-33. PubMed ID: 16177988
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological significance of DAPK gene promoter hypermethylation in non-small cell lung cancer: A meta-analysis.
Chen Z; Fan Y; Liu X; Shang X; Qi K; Zhang S
Int J Biol Markers; 2022 Mar; 37(1):47-57. PubMed ID: 34935548
[TBL] [Abstract][Full Text] [Related]
17. Does hypermethylation of CpG island in the promoter region of the E-cadherin gene increase the risk of lung cancer? A meta-analysis.
Sun Z; Liu G; Xu N
Thorac Cancer; 2019 Jan; 10(1):54-59. PubMed ID: 30390382
[TBL] [Abstract][Full Text] [Related]
18. Promoter-hypermethylation associated defective expression of E-cadherin in primary non-small cell lung cancer.
Wang G; Hu X; Lu C; Su C; Luo S; Luo ZW
Lung Cancer; 2008 Nov; 62(2):162-72. PubMed ID: 18468719
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological significance and potential drug target of O6-methylguanine-DNA methyltransferase in colorectal cancer: a meta-analysis.
Zheng CG; Jin C; Ye LC; Chen NZ; Chen ZJ
Tumour Biol; 2015 Aug; 36(8):5839-48. PubMed ID: 25716203
[TBL] [Abstract][Full Text] [Related]
20. Impact of smoking status on EGFR-TKI efficacy for advanced non-small-cell lung cancer in EGFR mutants: a meta-analysis.
Zhang Y; Kang S; Fang W; Hong S; Liang W; Yan Y; Qin T; Tang Y; Sheng J; Zhang L
Clin Lung Cancer; 2015 Mar; 16(2):144-151.e1. PubMed ID: 25454007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]